News

Analyses strengthen FLAME’s findings


 

At THE ERS CONGRESS 2016

References

Overall, the results from the FLAME post hoc analyses have demonstrated “remarkable consistency,” Dr. Wedzicha reported. Taken together, she said the data “imply that LABA/LAMA is the first choice of treatment for COPD patients at risk of exacerbation.”

Pages

Recommended Reading

Low doses may revive targeted therapy for chronic cough
MDedge Internal Medicine
Trials confirm benefits of triple COPD therapy
MDedge Internal Medicine
Noninvasive ventilation prevents rehospitalization in COPD patients
MDedge Internal Medicine
RPL-554 adds to short-acting drugs’ benefits in COPD
MDedge Internal Medicine
Benralizumab reduces exacerbations in pivotal severe asthma trials
MDedge Internal Medicine
Elevated HDL levels predict reduced lung function
MDedge Internal Medicine
Modified COPD assessment simplifies risk prediction
MDedge Internal Medicine
COPD patient characteristics predict response to maintenance drug
MDedge Internal Medicine
Simtuzumab did not help IPF patients
MDedge Internal Medicine
Decision rule identifies unprovoked VTE patients who can halt anticoagulation
MDedge Internal Medicine